Virological confirmation of suspected dengue in a Phase 2 Latin American vaccine trial: Implications for vaccine efficacy evaluation

Trials in Vaccinology

Volumn 3, Issue 1, 2014, Pages 127-133

  Boaz, Mark ^a   Janosczyk, Helene ^a   Garg, Seema ^a   Yost, Stacy ^a   Hildreth, Stephen W ^a   Dayan, Gustavo ^a   Starr Spires, Linda ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Dengue; Laboratory algorithm; PCR; Vaccine; Virological confirmation; Virus

Indexed keywords

DENGUE VACCINE; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 5; RECOMBINANT TETRAVALENT DENGUE VACCINE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADOLESCENT; ARTICLE; CHILD; DENGUE; DENGUE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION KIT; DENGUE VIRUS 2; DIAGNOSTIC KIT; DRUG EFFICACY; ELISA KIT; HUMAN; LABORATORY TEST; MULTICENTER STUDY (TOPIC); NONSTRUCTURAL PROTEIN 1 ELISA KIT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CONTROLLED STUDY; HIGH THROUGHPUT SEQUENCING; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION SYSTEM; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEROTYPE;

EID: 84905644169     PISSN: None     EISSN: 18794378     Source Type: Journal    
DOI: 10.1016/j.trivac.2014.07.002     Document Type: Article

References (24)

1. D.S. Burke, T.P. Monath, 4th ed., in: D.M. Knipe, P.M. Howley (Eds.), Fields Virology, Lippincott Williams & Wilkins: Philadelphia, PA, 2001; vol. 1, pp. 1043-1125.
2. World Health Organization (WHO). Dengue: guidelines for diagnosis, treatment, prevention and control. Available online: http://whqlibdoc.who.int/ publications/2009/9789241547871-eng.pdf (accessed on 1 August 2012).
3. J.L. San Martn, O. Braithwaite, and B. Zambrano et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality Am. J. Trop. Med. Hyg. 82 2010 128 135
4. Pan American Health Organization (PAHO). Dengue. Available online: http://new.paho.org/hq/index.php?option=com-content&task=view&id= 264&Itemid=363&lang=es (accessed on 1 August 2012).
5. F. Guirakhoo, R. Weltzin, and T.J. Chambers et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates J. Virol. 74 2000 5477 5485 (Pubitemid 30346579)
6. F. Guirakhoo, J. Arroyo, and K.V. Pugachev et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine J. Virol. 75 2001 7290 7304 (Pubitemid 32737987)
7. L.A. Villar, D.M. Rivera-Medina, and J.L. Arredondo-García et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, Phase II trial in Latin America Pediatr. Infect. Dis. J. 32 2013 1102 1109
8. E. Huhtamo, E. Hasu, and N.Y. Uzcatequi et al. Early diagnosis of dengue in travelers: comparison of a novel real-time RT-PCR, NS1 antigen detection and serology J. Clin. Virol. 47 2010 49 53
9. R.C. Edgar MUSCLE: multiple sequence alignment with high accuracy and high throughput Nucleic Acids Res. 32 2004 1792 1797 (Pubitemid 38832724)
10. A. Sabchareon, D. Wallace, C. Sirivichayakul, K. Limkittikul, P. Chanthavanich, S. Suvannadabba, V. Jiwariyavej, W. Dulyachai, K. Pengsaa, T.A. Wartel, A. Moureau, M. Saville, A. Bouckenooghe, S. Viviani, N.G. Tornieporth, and J. Lang Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled Phase 2b trial Lancet 380 2012 1559 1567
11. D.A. Steinhauer, and J.J. Holland Rapid evolution of RNA viruses Annu. Rev. Microbiol. 47 1987 409 433
12. C. Trevino, S. Bihon, and B.A. Pinsky A synonymous change in the influenza A virus neuraminidase gene interferes with PCR-based subtyping and oseltamivir resistance mutation detection J. Clin. Microbiol. 49 2011 3101 3102
13. R.Z. Capeding, I.A. Luna, and E. Bomasang et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled Phase I trial in the Philippines Vaccine 29 2011 3863 3872
14. Y.S. Leo, A. Wilder-Smith, and S. Archuleta et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore Hum. Vaccine Immunother. 8 2012 1259 1271
15. S.I. De la Cruz-Hernandez, H. Flores-Aquilar, and S. Gonzalez-Mateos et al. Determination of viremia and concentration of circulating nonstructural protein 1 in patients infected with dengue virus in Mexico Am. J. Trop. Med. Hyg. 88 2013 446 454
16. A.H. Ramirez, Z. Moros, and G. Comach et al. Evaluation of dengue NS1 antigen detection tests with acute sera from patients infected with dengue virus in Venezuela Diagn. Microbiol. Infect. Dis. 65 2009 247 253
17. K. Bessof, M. Delorey, and W. Sun et al. Comparison of two commercially available dengue virus (DENV) NS1 capture enzyme-linked immunosorbent assays for diagnosis of acute DENV infection with a single clinical sample Clin. Vaccine Immunol. 15 2008 1513 1518
18. V.T. Hang, N.M. Nguyet, and D.T. Trung et al. Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses PLoS Negl. Trop. Dis. 3 2009 e360
19. J. Hombach Guidelines for clinical trials of dengue vaccine in endemic areas J. Clin. Virol. 46 2009 S7 S9
20. R.S. Lanciotti, C.H. Calisher, and D.J. Gubler et al. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction J. Clin. Microbiol. 30 1992 545 551
21. S. Fahri, B. Yohan, and H. Trimarsanto et al. Molecular surveillance of dengue in Semarang, Indonesia revealed the circulation of an old genotype of dengue virus serotype-1 PLoS Negl. Trop. Dis. 7 2013 e2354
22. M.G. Castro, R.M. Nogueira, and A.M. Filippis et al. Dengue virus type 4 in Niterói, Rio de Janeiro: the role of molecular techniques in laboratory diagnosis and entomological surveillance Mem Inst Oswaldo Cruz 107 2012 940 945
23. Guidance for the Industry: Bioanalytical Method Validation. Washington, DC: US Department of Health and Human Services, FDA, CDER and CVM, 2001.
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. In: Validation of analytical procedures: Text and methodology. Topic Q2 (R1), Geneva, 2005.